Results 171 to 180 of about 1,969,671 (301)

TROP2‐Targeting Chimeras (TRTACs) for Tumor Cell‐Selective Membrane Protein Degradation and Enhanced Drug Delivery

Advanced Science, EarlyView.
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen, Xinying Fu, Wenqian Dong, Xiaobei Deng, Simin Chen, Fujun Wang, Jian Zhao, Shiqun Shao, Liqiang Fan, Jingyu Zhang, Lixin Zhang   +10 more
wiley   +1 more source

Precision immuno-oncology in NSCLC: integrating ADCs, therapeutic vaccines, and adoptive cell therapies for next-generation systemic treatment. [PDF]

Front Oncol
Garg P, Singhal SS.
europepmc   +1 more source

Therapeutic vaccines for human papillomavirus-related cancer: progress and challenges. [PDF]

Transl Cancer Res, 2022
Pagni RL, Pelegrin GF, Moreno ACR.
europepmc   +1 more source

A Model of Regulatory Burden in Technology Diffusion: The Case of Plant-Derived Vaccines. [PDF]

Plant-derived vaccines may soon displace conventional vaccines. Assuming there are no major technological barriers undermining the feasibility of this innovative technology, it is worthwhile to generate quantitative models of regulatory burden of ...
Bérard, Céline, Gold, Richard, Castle, David, Cloutier, Martin, Kumagai, Kira   +4 more
core  

Immune Checkpoint Inhibitor as a Fifth Component of Lipid Nanoparticles Enables Lymph Node‐Targeting and Augments mRNA Vaccine Efficacy

Advanced Science, EarlyView.
Here, a PDL1 inhibitor is employed as a fifth component to modify lipid nanoparticles (LNPs). PDL1 inhibitor‐loaded LNPs show enhanced lymph node targeting, resulting in greater lymph node expansion, immune cell infiltration, and improved mRNA vaccine efficacy. This fifth component LNP could be a novel platform for mRNA vaccines.
Minki Ha, Jaehyun Kim, Seyoung Kim, Gonna Somu Naidu, Sungchan Cho, Seok‐Beom Yong   +5 more
wiley   +1 more source

Toward cancer immunoprevention: what are the prospects for therapeutic vaccines? [PDF]

Ann Med Surg (Lond)
Tague C, Ekouo J, Makeda D, Yokolo H, Onesime J, Banga S, Kashafali A, Taj J, Akilimali A.   +8 more
europepmc   +1 more source

Nanotechnology in cervical cancer immunotherapy: Therapeutic vaccines and adoptive cell therapy. [PDF]

Front Pharmacol, 2022
Zhou X, Lian H, Li H, Fan M, Xu W, Jin Y.   +5 more
europepmc   +1 more source

Engineered Allosteric Biosensor for In Situ DNA Glycosylase Detection in Neuroblastoma Risk Stratification and Drug Resistance Monitoring

Advanced Science, EarlyView.
An engineered allosteric biosensor (UUU‐DZ‐tFNA) was developed, in which UDG specifically recognizes and activates a DNAzyme to achieve signal cycle amplification in a sequentially activatable mode. UUU‐DZ‐tFNA achieves in situ UDG detection across multiple biological levels and facilitates risk stratification and drug resistance monitoring of NB ...
Yaqing Lu, Yingyu Zhang, Xianwei Zhang, Mengxin Zhang, Fei Zhang, Jushan Sun, Yahui Yang, Kangbo Liu, Peng Wang, Shuying Luo, Wancun Zhang   +10 more
wiley   +1 more source

TLR9-activating cholesterol azetidine derivative-assisted therapeutic vaccines for cancer immunotherapy. [PDF]

Sci Adv
Chen J, Su M, Yu B, Yang M, Wang H, Yang X, Wang J.   +6 more
europepmc   +1 more source

New Perspectives in Therapeutic Vaccines for HPV: A Critical Review. [PDF]

Medicina (Kaunas), 2022
Gardella B, Gritti A, Soleymaninejadian E, Pasquali MF, Riemma G, La Verde M, Schettino MT, Fortunato N, Torella M, Dominoni M.   +9 more
europepmc   +1 more source